National Veterinary Institute, Uppsala, Sweden.
Acta Vet Scand. 2011 Mar 25;53(1):22. doi: 10.1186/1751-0147-53-22.
United Kingdom, Ireland, Malta and Sweden maintain their national provisions for a transitional period regarding rules concerning rabies vaccination and individual serological test for rabies neutralizing antibodies. The purpose of vaccinating dogs against rabies is to establish pre-exposure immunity and protect individual animals from contracting rabies.The aim of the study was to investigate factors associated with reaching the internationally accepted threshold antibody titre of 0.5 IU/mL after rabies vaccination of dogs.
The study was a prospective single cohort study including 6,789 samples from Swedish dogs vaccinated with commercially available vaccines in Sweden, and the dog's antibody responses were determined by the OIE approved FAVN test. Information on potential risk factors; breed, age, gender, date of vaccination, vaccine label and the number of vaccinations, was collected for each dog. Associations between the dependent variable, serological response ≥ 0.5 IU/mL or < 0.5 IU/mL and each of the potential risk factors were investigated using logistic regression analysis.
Of 6,789 vaccinated dogs, 6,241 (91.9%) had an approved test result of ≥ 0.5 IU/mL. The results of the multivariable logistic regression analysis showed that vaccinating with vaccine B reduced the risk of having antibody titres of < 0.5 IU/mL by 0.2 times compared with vaccination using vaccine A. Breed size was found significant as an interaction with number of vaccinations and age at vaccination as an interaction with day of antibody testing after last vaccination. In summary, larger breeds were at higher risk of having antibody titres of < 0.5 IU/mL but if vaccinated twice this risk was reduced. Moreover, there were a increased risk for dogs < 6 months of age and > 5 years of age to have antibody titres of < 0.5 IU/mL, but this was affected by number of days from vaccination till testing.
The probability of success of rabies vaccinations of dogs depends on type of vaccine used, number of rabies vaccinations, the breed size of the dog, age at vaccination, and number of days after vaccination when the antibody titres are tested. The need for a booster vaccination regimen is recommended for larger breeds of dog.
英国、爱尔兰、马耳他和瑞典在狂犬病疫苗接种和狂犬病中和抗体个体血清学检测规则方面维持国家规定的过渡期。给狗接种狂犬病疫苗的目的是建立暴露前免疫,保护个体动物免受狂犬病感染。本研究的目的是调查与狗接种狂犬病疫苗后达到国际公认的 0.5IU/ml 抗体效价阈值相关的因素。
这是一项前瞻性单队列研究,纳入了瑞典使用市售疫苗接种的 6789 只狗的样本,并用 OIE 批准的 FAVN 试验测定狗的抗体反应。为每只狗收集了潜在危险因素的信息,包括品种、年龄、性别、接种日期、疫苗标签和接种次数。使用逻辑回归分析调查了因变量(血清学反应≥0.5IU/ml 或<0.5IU/ml)与每个潜在危险因素之间的关系。
在 6789 只接种疫苗的狗中,6241 只(91.9%)的批准检测结果≥0.5IU/ml。多变量逻辑回归分析结果显示,与使用疫苗 A 相比,使用疫苗 B 接种可将抗体效价<0.5IU/ml 的风险降低 0.2 倍。犬种体型与接种次数之间存在显著交互作用,年龄与最后一次接种后检测抗体的天数之间存在显著交互作用。总的来说,较大的犬种有较低的风险,但如果接种两次,这种风险会降低。此外,6 个月以下和 5 岁以上的狗的抗体效价<0.5IU/ml 的风险增加,但这受到从接种到检测的天数的影响。
狗狂犬病疫苗接种的成功率取决于所用疫苗的类型、狂犬病疫苗接种次数、犬种体型、接种年龄以及检测抗体时的接种后天数。建议为大型犬种接种加强疫苗。